Assessing the impact of HBV NAT on window period reduction and residual risk.
Kleinman
Steven H
SH
Kleinman BioMedical Consulting, Victoria, BC, Canada.
Busch
Michael P
MP
D006509:Hepatitis B / Q000453:epidemiology / Q000517:prevention & control / Q000635:transmission*; D006515:Hepatitis B virus / Q000235:genetics / Q000302:isolation & purification; D006801:Humans; D021141:Nucleic Acid Amplification Techniques; D012307:Risk Factors